The half-used bags of prescription food stacked in the garage are familiar territory for anyone who lives with a dog that has inflammatory bowel disease. You try a novel protein for eight weeks. Things improve, then slide. A steroid helps until the dose tapers, and six months later you are back in the same exam room.
That loop is why a small placebo-controlled trial reported on October 26 is worth a look. The results were strong enough to earn the drug’s developer a faster route through the FDA.
What chronic enteropathy actually is
Vets call it chronic inflammatory enteropathy, or CIE. The label covers several relapsing conditions where the immune system keeps the gut lining inflamed. Signs owners know too well: vomiting, diarrhea, weight loss, and a dog who is hungry but not gaining.
Diagnosis is a process of elimination: parasites ruled out, a diet trial, then ultrasound and bloodwork for B12 and folate, sometimes biopsies. Only after the other explanations are gone does the label stick.
There is no FDA-approved drug for canine CIE. Treatment leans on hydrolyzed or novel-protein diets plus long-term steroids or other immunosuppressants, and a fair number of dogs never settle. VETmAb Biosciences estimates 1.7 million US dogs have the condition, citing claims data that puts digestive problems second among reasons dogs see a vet.
The drug and why it targets IL-23
VMB-C001a, from San Diego-based VETmAb Biosciences, is a monoclonal antibody given as an injection. It blocks interleukin-23, a signaling protein that keeps a group of inflammatory immune cells called Th17 cells active in the gut wall. Shut down IL-23 and that loop loses its driver.
If the logic sounds borrowed, it is. Three IL-23 blockers (risankizumab, guselkumab and mirikizumab) are approved for Crohn’s disease or ulcerative colitis in people, where the same pathway does the same damage. VETmAb’s bet is that a canine version of a proven human gut-drug target can clear the bar. Its founders built Kindred Biosciences, later bought by Elanco.
What the 105-day trial showed
Nineteen dogs with naturally occurring CIE took part. Nine received the drug and ten a placebo, with owners and vets blinded. Visits ran at days 0, 14, 45, 75 and 105.
Success meant at least a 25% drop in the dog’s CIBDAI score, a standard index covering attitude, appetite, vomiting, stool consistency, frequency and weight, averaged across days 75 to 105. Any dog needing other medication or supplements for gut signs counted as a failure.
77.8% of treated dogs met that bar, against 30% on placebo. Of the treated dogs, 66.7% had a partial response and 11.1% reached full remission, meaning more than a 75% improvement. No placebo dog reached remission.
Side effects were thin on the ground. One treated dog yelped during an injection on day 75, and everything else reported was mild and judged unrelated. One placebo dog was euthanized on day 105 as the disease progressed.
What the FDA decision does and does not mean
The drug has been granted eligibility for the FDA’s expanded conditional approval pathway. That is not an approval, and it is not a promise of one. Under the pathway, a company can market a drug after proving safety to the full standard and showing a reasonable expectation that it works, while it finishes the larger effectiveness studies. Conditional approvals run one year at a time, with up to four renewals and a five-year ceiling to reach full approval.
Four animal drugs have gone through this route so far, for epilepsy, heart failure, acute pancreatitis and anemia tied to chronic kidney disease. It exists because big effectiveness trials in pets are slow and expensive, and the alternative is often no product.
What this means for your dog
Nothing changes this month. There is no product to ask about, no price, and no launch date. The next step is a pivotal study, and conditional approval, if it comes, would follow that.
If your dog has ongoing gut signs, the useful work is diagnostic, not pharmaceutical. Chronic diarrhea that comes and goes deserves a proper workup, not another round of bland food, and our guide to when acute diarrhea in dogs needs a vet covers the red flags that mean same-day care. A diet trial only counts when it is strict for the full eight weeks, and probiotics during a course of antibiotics are a different question from immune-driven disease.
The placebo number is worth sitting with. Three in ten dogs on a dummy injection still improved by the trial’s own measure, which is a reminder of how much careful feeding, regular weighing and steady follow-up do on their own.
For the wider picture on gut and immune health, the K9 Pie Dog Health 101 hub collects the basics. And whatever you read here, talk to your vet before changing anything for a dog who is already on steroids or a prescription diet.
What to watch next
The next trial will matter more than this pilot did. Nineteen dogs can show a signal, but they cannot prove a drug works across messy real cases or surface rare side effects. Watch the enrollment size and how long follow-up runs, and whether success holds when dogs stay on their usual diets.
If VMB-C001a does reach the market, expect internal medicine specialists and referral hospitals to have it first, with a price closer to other biologics than to a course of prednisolone.